Adaptive Biotechnologies ($ADPT) Insider Trading & Smart Money Activity
Adaptive Biotechnologies Corporation ($ADPT) has 21 insider trades, 2 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 6 insiders sold ($9.47M), net -$9.47M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 6
- Net insider $ (12 mo)
- -$9.47M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 1
ADPT insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 4 · $1.50M | 0 / 0 | 2 / 0 |
| Q3 2026 | 0 | 1 · $3.24M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 14 · $4.73M | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ADPT insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $288.01K | -3.05% | SEC | Read | ||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $304.27K | -3.05% | SEC | Read | ||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $305.07K | -3.05% | SEC | Read | ||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $302.97K | Read | ||||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $303.13K | Read | ||||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $313.78K | -9.3% | Read | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $304.87K | -2.0% | — | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $313.66K | -2.5% | — | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $329.70K | -6.0% | — | |||||
| Insider | Susan BobulskyChief Commercial Officer, MRD | Sell (Open-market sale) 10b5-1 | 6.44K sh | $193.32K | -6.0% | — | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $346.81K | -14.3% | — | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $334.21K | -6.6% | — | |||||
| Insider | Julie RubinsteinPresident and COO | Sell (Open-market sale) 10b5-1 | 11.88K sh | $333.30K | -4.7% | — | |||||
| Insider | Francis LoChief People Officer | Sell (Open-market sale) 10b5-1 | 26.79K sh | $757.70K | -4.7% | — | |||||
| Insider | Francis LoChief People Officer | Sell (Open-market sale) 10b5-1 | 115.41K sh | $3.24M | +0.8% | -13.2% | — | ||||
| Insider | Sharon BenzenoChief Commercial Ofc Imm Med | Sell (Option exercise) | 103.30K sh | +0.5% | +5.4% | — | |||||
| Insider | Sharon BenzenoChief Commercial Ofc Imm Med | Buy (Option exercise) | 103.30K sh | $751.61K | +0.5% | +5.4% | Read | ||||
| Analyst | Guggenheim | Reiterates to buy | PT $22 | +0.5% | +5.4% | Read | |||||
| Insider | Sharon BenzenoChief Commercial Ofc Imm Med | Sell (Open-market sale) 10b5-1 | 11.03K sh | $231.71K | +2.6% | +7.5% | Read | ||||
| Insider | Griffin Michelle Renee | Sell (Open-market sale) 10b5-1 | 52.08K sh | $1.05M | +4.6% | +11.3% | Read | ||||
| Insider | Susan BobulskyChief Commercial Officer, MRD | Sell (Open-market sale) 10b5-1 | 5K sh | $102.50K | +4.6% | +11.3% | Read | ||||
| Insider | Harlan RobinsChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 6.16K sh | $110.94K | +0.1% | +28.3% | Read | ||||
| 13F | Jane Street Group | New | +682.18K sh | $12.78M | -4.9% | +37.4% | — | ||||
| 13F | Jane Street Group | New | +682.18K sh | $14.35M | -4.9% | +37.4% | — |
1W / 1M / 6M = how ADPT moved from the trade or filing date.
Insider trading in ADPT: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Julie Rubinstein | President and COO | 12 | -$3.78M | 377.80K | Oct 16, 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | 2 | -$295.82K | Oct 6, 2026 | |
| Francis Lo | Chief People Officer | 2 | -$4M | Oct 1, 2026 | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 3 | -$231.71K | Jun 29, 2026 | |
| Griffin Michelle Renee | 1 | -$1.05M | Jun 25, 2026 | ||
| Harlan Robins | Chief Scientific Officer | 1 | -$110.94K | Jun 16, 2026 |
Institutions moving ADPT (13F)
Analyst ratings on ADPT
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Guggenheim | Reiterates | buy | $22 | +0.5% | +5.4% | Read |
Frequently asked questions
Are ADPT insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 6 insiders made 19 open-market sales worth $9.47M, a net -$9.47M.
What is the latest insider trade in ADPT?
Julie Rubinstein, President and COO filed a sell (open-market sale) of 11.88K sh worth $288.01K on Oct 16, 2026.
Which institutions changed their ADPT positions?
Recent 13F filers moving the stock include Jane Street Group.
Other diagnostics & research stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.